Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.
Bosutinib is an orally bioavailable SRC/ABL tyrosine kinase inhibitor with activity against all phases of resistant chronic myeloid leukemia that do not express the T315I or V299L ABL kinase domain mutations. Bosutinib has a unique toxicity profile that is manageable. This paper provides an overview of bosutinib, covering pharmacodynamics and pharmacokinetic properties, results of treatment in newly diagnosed and previously treated chronic myeloid leukemia patients, as well as common side effects.
Office of Clinical Trials, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Ann Q
AQ
Shen
Department of Pharmacy, Emory University Hospital, Atlanta, GA, USA.
Nicole M
NM
Wilson
Office of Clinical Trials, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Shannon L
SL
Gleason
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365C Clifton Road, Suite C1152, Atlanta, GA 30322, USA.
Hanna Jean
HJ
Khoury
bosutinib; chronic myeloid leukemia (CML); pharmacodynamic; pharmacokinetic; safety; tolerability; tyrosine kinase inhibitors (TKIs)